MEIP
$3.53
Mei Pharma
$.28
8.62%
MEIP
Earnings Whisper ®
N/A
1st Quarter September 2020
Consensus:  ($0.07)
Revenue:  $0.00 Mil
Wednesday
Dec 9
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MEIP reports earnings?
Beat
Meet
Miss

Where is MEIP's stock price going from here?
Up
Flat
Down
Stock chart of MEIP
Analysts
Summary of analysts' recommendations for MEIP
Score
Grade
Pivots
Resistance
$3.97
$3.77
$3.65

$3.45

Support
$3.33
$3.13
$3.01
Tweet
Growth
Description
MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego.
Peers
InterCeptRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonZoetisUltragenyx PharmaceuticalBristol-Myers SquibbCatalentMerck & Co.